3Robert TN,Bruce Wisely G, Stefan W,et al.Ligand binding and co-activatorassembly of the peroxisome proliferator-activated receptor. Nature, 1998,395:137
4Plosker GL, Fanlds D. Troglitazone:a review of its use in the management of type 2 diabetes mellitus. Drugs, 1999,57(3):410
5Spencer CM, Markham A.Troglitazone. Drugs, 1997,54(1):89
5Izumi I, Hosiyama K, Enomoto S, et al. Pharmacokinetics of troglitazone, an antidiabetic agent: prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data. J Pharmacol Exp Ther, 1997, 280:1392-1400.
6Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med, 2001, 111 :10-17.
7Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care , 2000, 23: 1605-1611.
8Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther, 2000 , 22: 1395-1409.
9Rubin C, Egan J, Schneider R. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes. Diabetes,1999 , 48 Suppl 1:A110.
10Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care, 1999, 22:288-293.
